Register for OBR daily


To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

PARD $0.34 0.1299 +61.86%
AGIO $43.66 3.3100 +8.20%
PVCT $0.98 0.0701 +7.70%
GALT $5.22 0.3600 +7.41%
SPPI $7.91 0.4000 +5.33%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

CBMG $17.00 -1.7700 -9.43%
IMNP $3.74 -0.2099 -5.31%
CRIS $1.59 -0.0650 -3.94%
CERU $4.49 -0.1800 -3.85%
GALE $2.15 -0.0500 -2.27%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | Next > | Last >>

EMA Approves Eisai's Lenvatinib For Accelerated Assessment in Radioiodine-Refractory Differentiated Thyroid Cancer

(MarketWatch) July 30, 2014 - The European Medicines Agency (EMA) has approved Eisai's request for accelerated assessment of the investigational oral multiple receptor tyrosine kinase (RTK) inhibitor lenvatinib, for the treatment of patients with progressive radioiodine-refractory, differentiated thyroid cancer (RR-DTC).
read article 

AstraZeneca Steps Up Push Into Cancer Immunotherapy

(Reuters) July 31, 2014 - AstraZeneca is accelerating its push into cancer immunotherapy, with plans to test a key experimental drug in new tumor types.
read article 

Erytech Enrolls First Patient in Phase II Study of ERY-ASP in Pancreatic Cancer

(Pharmaceutical Business Review) July 30, 2014 - ERYTECH Pharma has announced the enrollment of the first patient in its Phase II study with ERY-ASP in second line treatment of patients affected by pancreatic cancer.
read article 

Target Growth-Driving Cells Within Tumors, Not Fastest-Proliferating Cells, New Study Suggests

(Dana-Farber) July 30, 2014 - A Dana-Farber study shows growth-driving cancer cells may be better targets for therapies than cells that proliferate the fastest within the tumor.
read press release 

Navigators Can Help Guide Breast Cancer Patients Through Care

(Reuters Health) July 30, 2014 - Patient navigators may be able to help steer women with breast cancer through what can be a daunting treatment process, a new study suggests.
read article 

Same Cancer, Different Time Zone

(MD Anderson) July 30, 2014 - Just as no two people possess the same genetic makeup, a recent study has shown that no two single tumor cells in breast cancer patients have an identical genome.
read press release 

Cause of Rare Childhood Cancer Discovered

(University of Aberdeen [Scotland]) July 31, 2014 - Scientists have made a breakthrough in understanding the cause of a rare childhood muscle cancer, called Rhabdomyosarcoma (RMS).
read press release 

Transplantation Shown to Be Highly Effective in Treating Severe Combined Immunodeficiency

(MSKCC/On Cancer blog) July 31, 2014 - A study shows that treatment of severe combined immunodeficiency (SCID) with stem cell transplantation is very effective, especially if done early.
read article 

Researchers See Promise For Two New Therapies For Mantle Cell Lymphoma After Discovering Why Tumors Can Become Resistant to a Newly Approved Treatment

(Weill Cornell) July 31, 2014 - A research team led by Weill Cornell Medical College has revealed key insight into why late resistance to ibrutinib occurs. And it has shown in preclinical studies that two different drug-treatment strategies may be useful for patients in whom the drug does not work.
read press release 

New NICE Knockback For Celgene Myeloma Drug

(PharmaTimes [UK]) July 31, 2014 - The National Institute for Health and Clinical Excellence is consulting once again on the use of Celgene’s Revlimid (lenalidomide) in the treatment of multiple myeloma following one prior treatment with Johnson & Johnson’s Velcade (bortezomib), as it issued a second draft guidance not recommending it in this use.
read article 

Johnson & Johnson Pulls Hysterectomy Device From Hospitals

(Wall Street Journal) July 30, 2014 - Johnson & Johnson, which already suspended sales of a surgical tool that has been blamed for spreading a dangerous cancer in women, now plans to tell doctors world-wide to return any devices currently on shelves.
read article (paid subscription required) 

Prostate Cancer Probe to Ease Impotence Opposed by Panel

(BloombergBusinessweek) July 31, 2014 - EDAP TMS SA, the maker of an ultrasound device to treat prostate cancer with lower rates of erectile dysfunction, lost almost half its market value after the product failed to win a U.S. advisory panel’s backing.
read article 

Amgen Plans to Cut Up to 2,900 Jobs

(MarketWatch/Dow Jones Newswires) July 30, 2014 - Amgen Inc. said it plans to reduce its global workforce by 12% to 15% and close facilities in two states as part of a restructuring that aims to focus resources on developing new drugs.
read article 

AstraZeneca Buys Almirall Lung Drugs for Up to $2.1 Billion

(Reuters) July 30, 2014 - AstraZeneca took a major step to build up its respiratory medicine business on Wednesday by striking a deal worth up to $2.1 billion for the rights to Spanish group Almirall's lung drugs.
read article 

Pfizer Scores Vaccine Expansion with Baxter’s Portfolio

(The Utah People's Post) July 30, 2014 - It would seem that yet again Pfizer got the long straw as they landed the expansion they had been dreaming of.
read article 

Sanofi Cholesterol Drug Meets Main Goal of 9 Trials

(BloombergBusinessWeek) July 30, 2014 - Sanofi and Regeneron Pharmaceuticals Inc.’s cholesterol drug cut levels of the artery-clogging protein in nine trials, and reduced the rate of heart attack, stroke and death in one test, as the companies race with Amgen Inc. to get a new treatment to market.
read article 

Regeneron Gains as Eye Drug Approved for Expanded Use

(Bloomberg) July 30, 2014 - Regeneron Pharmaceuticals Inc. shares climbed the most since January after U.S. regulators approved its eye injection Eylea for use against diabetic macular edema, a disease in 1.5 million Americans that’s linked to vision loss.
read article 

Researchers Fret as Social Media Lift Veil on Drug Trials

(Wall Street Journal) July 29, 2014 - On her first day in a clinical trial for an experimental multiple sclerosis drug, Jeri Burtchell was convinced she was getting the new drug, not the standard therapy that some patients were randomly assigned to receive.
read article (paid subscription required) 

Expert Panel Recommends Sweeping Changes To Doctor Training System

(Kaiser Health News) July 29, 2014 - An expert panel recommended Tuesday completely overhauling the way government pays for the training of doctors, saying the current $15 billion system is failing to produce the medical workforce the nation needs.
read article 

Lymphoma Research Foundation Announces Launch of Lymphoma Education and Advocacy Partners (LEAP)

(PRWeb) July 29, 2014 - Foundation convenes lymphoma-specific advocacy organizations to impact public policies that affect lymphoma patients and their cancer care.
read press release 

NCCN Offers Free Webinars for Patients with Non-Small Cell Lung Cancer

(NCCN) July 24, 2014 - On August 16, 2014, NCCN will host the second of two free patient information webinars designed to allow patients and their caregivers the opportunity to listen to live expert discussions about non-small cell lung cancer.
read press release 

Sen. Harkin Introduces Accelerating Biomedical Research Act

(ASCO in Action) July 29, 2014 - Sen. Tom Harkin (D-Iowa) has introduced the Accelerating Biomedical Research Act that would give Congress the authority to boost the budget of the National Institutes of Health to $46.2 billion by 2021.
read article 

CMS Approval, New Platform Making QOPI® Participation Easier

(ASCO in Action) July 29, 2014 - ASCO’s Quality Oncology Practice Initiative (QOPI®) is transforming to meet the reporting needs of its members. The approval of new reporting pathways by the Centers for Medicare and Medicaid Services (CMS), along with a new QOPI platform, will offer new opportunities for practices participating or wishing to participate in the fall QOPI round beginning on September 18.
read article 

Researcher Skips Treatment to 'Immortalize' Her Own Cancer

(Medscape Medical News) July 29, 2014 - A biomedical researcher with an unusually virulent form of breast cancer has taken an extraordinary step to "immortalize" her cancer cells.
read article (free registration required) 

It's Not Just About Survival: Why Some Breast Cancer Patients Opt For Surgery on Both Sides

(Forbes) July 29, 2014 - Most women do well, for many years, after the smallest surgery possible to remove an invasive breast tumor. But the decision isn’t easy.
read article